Article

Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial

2024-02-03

Abstract excerpt

<h4>Summary</h4> The HIPRA-HH-2 was a multicentre, randomized, active-controlled, double-blind, non-inferiority phase IIb clinical trial to compare the immunogenicity and safety of a heterologous booster with PHH-1V adjuvanted recombinant vaccine versus a homologous booster with mRNA vaccine. Interim results showed a strong humoral and cellular immune response against the SARS-CoV-2 Wuhan-Hu-1 strain and the Beta,...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a0fb66e1-ec15-5710-bc73-eae43fb3631f
DOI: 10.1101/2024.02.01.24302052

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trialDOI 10.1101/2024.02.01.24302052Read

Humoral Immune Response Against Sars-Cov-2 Variants (Omicron Ba.1, Ba.4/5, Beta and Delta) of Phh-1v Booster Vaccine in Subjects Previously Vaccinated with a Mrna Vaccine. Results of a Randomised Controlled Trial Up to 6 MonthsSemantic proximity Read

Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trialSemantic proximity Read

SAFETY AND IMMUNOGENICITY OF A PHH-1V BOOSTER DOSE AFTER DIFFERENT PRIME VACCINATION SCHEMES AGAINST COVID-19: PHASE III CLINICAL TRIAL FINAL RESULTS UP TO ONE YEARSemantic proximity Read

Preclinical evaluation of PHH-1V vaccine candidate against SARS-CoV-2 in non-human primatesSemantic proximity Read

Safety and Immunogenicity of a Recombinant Protein RBD Fusion Heterodimer Vaccine against SARS-CoV-2: preliminary results of a phase 1-2a dose-escalating, randomized, double-blind clinical trialSemantic proximity Read

Immunogenicity and Safety of PHH-1V COVID-19 Vaccine as a Heterologous Booster in AdolescentsSemantic proximity Read

Humoral Immune Response Against XBB.1.5 and BQ.1.1 SARS-COV-2 Variants of a Fourth Dose of PHH-1V Vaccine in Adult Subject: Preliminary Results of HIPRA-HH-2 Extension StudySemantic proximity Read

Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trialSemantic proximity Read

Efficacy of Heterologous Boosting Using Recombinant SARS-CoV-2 Fusion Protein Vaccine: A Randomized, Double-Blind and Placebo-Controlled Phase III TrialSemantic proximity Read

An in-depth investigation of the safety and immunogenicity of an inactivated SARS-CoV-2 vaccineSemantic proximity Read

Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccinationSemantic proximity Read

Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled TrialSemantic proximity Read